Amicus Therapeutics Inc. (FOLD)
9.11
-0.45 (-4.71%)
At close: Feb 20, 2025, 3:59 PM
9.06
-0.49%
After-hours: Feb 20, 2025, 06:11 PM EST
undefined% (undefined)
| Bid | 9.05 |
| Market Cap | 2.72B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.18 |
| PE Ratio (ttm) | -50.58 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 9.14 |
| Volume | 2,469,400 |
| Avg. Volume (20D) | 2,325,245 |
| Open | 9.40 |
| Previous Close | 9.56 |
| Day's Range | 9.05 - 9.63 |
| 52-Week Range | 8.79 - 14.02 |
| Beta | undefined |
About FOLD
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzym...
Industry Biotechnology
Sector Healthcare
IPO Date May 31, 2007
Employees 500
Stock Exchange NASDAQ
Ticker Symbol FOLD
Website https://amicusrx.com
Analyst Forecast
According to 9 analyst ratings, the average rating for FOLD stock is "Buy." The 12-month stock price forecast is $17, which is an increase of 86.71% from the latest price.
Buy 77.78%
Hold 22.22%
Sell 0.00%
Next Earnings Release
Amicus Therapeutics Inc. is scheduled to release its earnings on May 8, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
+14%
Amicus Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
6 months ago
+13.2%
Amicus Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY24 revenue guidance.
